

EASTWOOD BIO-MEDICAL CANADA INC.

#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-Medical Canada Reflects on Q3 2018 and Entry into Asian Market

October 1, 2018 – Richmond, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) published consolidated financial statements and Management’s Discussion and Analysis for the fiscal quarter ending July 31, 2018. They are available under the Company’s profile on SEDAR at www.sedar.com.

The Company has advanced its business strategy on several fronts during this fiscal year. Since April 2018, the Company has announced the introduction of almost fifty new products, expanding the Eleotin® brand presence in Canada from nine products in 2014 to the current count of 68 products. With these products the Company expects to meet market demands for cognitive health issues, cholesterol products, and cannabis products.

The Company also announced in April the acquisition of Good Manufacturing Practices (GMP) compliant Health Canada and foreign site licensed facilities, which are expected to save the Company up to \$7 million in manufacturing costs.

Yunji Kim, President and CEO, commented, “It was no accident that product approvals from the South Korean government and entering terms with an Asian distributor followed this acquisition. We have been preparing to meet the potential market demand for our products. But the Asian market is a highly educated one that wants premium products. It was extremely important for us to be able to operate a facility that can produce higher end products.

The facilities and our preparation for new markets is what made possible the recent shipment of capsuled products and nutraceutical tea products, each respectively valuing at about \$450,000 and \$100,000 in consumer retail value to Korea. Eleotin® products recently generated \$30,000 in sales in a four-day period this September. Initial unaudited reports from distributors approximate September sales to Korean consumers to be a little over \$250,000. As a result, the Company has started to prepare a series of shipments of Eleotin® products to Asia during October and November. The recent display of the potential demand for Eleotin® have been encouraging. We expect to see the effect of these recent events to show in our next quarterly reports once the numbers are finalized. While cautiously optimistic, we, of course, do not know at this early stage whether these numbers are indicative of any long term trend in future performance. And initial distributor report numbers are not subject to audit. But we would like to interpret them as a reason to keep working aggressively towards our goals and ending the next quarter on a strong note.”

About Eastwood Bio-Medical Canada, Inc.:

The Company is a Vancouver based company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin® was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on the cause, cure, and prevention of Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People's Republic of China. Eleotin® products have been endorsed by thousands of doctors and diabetes associations around the globe.

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.